Member Info for MU345

Nothing can be rolled out until MHRA approval achieved, which will the allow a government order. BBI have already leaked the order.

Ideal scenario the government don’t want the tests and we can sell predominantly private. But I doubt that will be the case unfortunately, the government consortium wasn’t set up to provide a gold standard test to not be rolled out by the government.

Exactly, why would the government by interested in a test which is far less accurate than the RTC gold standard test.

Some people need it spelling out in an RNS though.

Im grateful to the spooked for those buys earlier. Just wish I got more..

But to put that in context, I hadn’t averaged up since buying heavily during the placing, until today. This is now in a brilliant position and I don’t think there’s been a better time to be invested in truth.

Hopefully not.

The less clueless traders here the better.

Just offloaded my GDR and sent it straight into ODX.

Bargain territory.

I rarely average up.. but this one is just slapping me in the face with buy signals.

Looks as though LON:FAB have realised the importance of antibodies in the fight against covid.

Note - Not Invested there. ODX has been 80% of my PF since June.

But again reinforcing the importance of the gold standard antibody tests.

Talk about right place at the right time. The opportunity provided to Omega is quite remarkable. Substantial demand for testing Increasing daily just as we’ve reached the next level of capacity at 500,000 tests per week. Competition failing to deliver.. MHRA imminent, to then allow confirmation of the government orders. Allocation to then be provided to other tests and contracts. Antibodies becoming even more purposeful with each study...

Funding complete and fully cashed up. Speeding tickets paid. Sneller the seller who’s been donating shares all the way from 40p has almost finished his charitable work... numerous catalysts primed to send the SP ballistic.

If there’s ever been a time to be invested...

“This message has been filtered, please adjust your filters to view”. - sometimes forget how useful the filter option is, great tool.

Almost thinking this could be the worst time for the SP. Cusp of second wave, testing problems, local lockdowns, announced losses, winter months approaching ect ect... will have to wait and see. I’ll be adding increasingly if it continues to fall however. I have no intention to sell for years so share price is nothing other than a buying opportunity. GL.

Strong consolidation after the recent rise. Target in play prior to news is 110p according to charts. Hopefully looking to close in the mid 90s+ today, especially with FOMO for the week ahead.

ODX have so much going on, just need to clear this final MHRA hurdle and other developments will follow in quick succession imo.

Currently sat at 52 week low. Picked up a few tranches earlier in the week. With a couple of orders on in case of a further drop.

I think lack of PR is potentially what’s dragging this down but providing a good buying opportunity.

Last time it hit 1.50 it rose over 100% in a month.

What’s the betting this finishes blue?

Everyone has been waiting for the placing to load up, and as rightly pointed out, it’ll be yesterday’s news.

Oh dear.. I think your money is probably better in premium bonds Sujood.

Lovely little top up. Thanks very much.

For me, December/ January is and always has been prime time for the SP on a short term outlook. At which point ODX should be producing circa 2,000,000 tests per week. At which point I’d expect the SP to be multiples of the current.

Each to their own. But selling out whilst at around 25% of future manufacturing capacity, awaiting gov orders, global orders, MHRA approval, WHO approval, antigen testing ect ect ect. Especially as the need for testing grows during winter and as the second wave grows more rampant.

But to sit back and watch the SP go exponential over the next few months... wouldn’t wish that on my worst enemy.

Everyone wants everything here and now, it’s hilarious.

Good things come to those who wait.

But to be honest this one couldn’t be much clearer. Really do just have to sit on your hands, apart from picking up on any dips of course.

The government are under immense pressure to ensure there is an effective testing regime especially as we head into what looks like a second wave on the cusp of the winter months which were always going to be a struggle. Lives and livelihoods are at stake, so the need for mass high quality testing right now is absolutely crucial.

Everywhere I look testing is the talk of the town. I was listening to Piers this morning grilling someone on the testing strategy (or lack of).

I fully expect you can rest assured that MHRA approval will be moving as fast as it can along with all other on going developments. Once granted, get your reading glasses on because news will come thick and fast.

Omega have recently upped capacity and are well on the road to the substantial 2,000,000+ per week. The RTC test is just about to clear the final hurdle after months of validations and verifications. iAbra’s test has been deemed almost useless upon false information regarding accuracy, potentially putting Mologic in the spot light with regard to airport testing for the antigen test. Mologic antibody test shortly to receive WHO approval. Amongst numerous other catalysts.

Forget the recent rise, ODX should have been £1 months ago, now is the time to be in.

Any chance I could have a lend of that crystal ball?

“My point is just look at where nyct is and what they’ve achieved.”

Alternatively, look at AVCT’s half a billion mcap and what they’ve achieved.

Not that your statement doesn’t suggest substantial growth for ODX, but not sure you can compare as easily as that.

ODX have Food Intolerance and CD4 testing due to rise exponentially in sales over the next few years. Do NCYT have other elements to their business portfolio such as this?

Likewise are NCYT producing in excess of 2,000,000 tests per week or planned to be? With what will be an armoury of at least 5 of the top tier tests on the market?

Achievable price targets remain multiples of the current, and rightly so.

In regard to iAbra:

Jon Deeks, professor of biostatistics at Birmingham university, said, “we are in a pandemic, people are dying from the disease, and a company decides that it is reasonable to mislead us all to make their test look like the best thing available”, referring to the claims being made for the test’s accuracy.

Looks like the mologic test could be the most suitable candidate after all.

“Work by spreading discontent amongst investors trying to disrupt the boards, that's how shorting works. For a short to work out its a classic play to takeover the bb in the hope you sell out forcing the price lower’”

I forgot this was a bb, as oppose to _GazK’s personal diary, cannot get a word in edgeways.